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Abstract. Neural stem cells are multi-potent and able to self renew to maintain its character throughout the life. Loss of self
renewal ability of stem cells prevents recovery or replacement of cells damaged by disease with new cells. The Niemann-Pick
type C1 (NPC1) disease is one of the neurodegenerative diseases, caused by a mutation of NPC1 gene which affects the function
of NPC1 protein. We reported that NPC 1 gene deficiency could lead to lack of the self renewal ability of neural stem cells in
Niemann pick type C disease. We also investigated many genes which are involved in stem cells proliferation and differentiation
by gene profile in NPC mice.
Diagnosis of NPC disease is difficult because it is accompanied by complicated symptoms and the fact that there is no effective
treatment for NPC patients. Studies of these stem cells and their relationship to Niemann pick type C disease will provide new
biomarkers for early diagnosis as well as a potential cure by use of targeted therapeutics for Niemann pick type C disease.
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1. Introduction
Niemann pick type C disease is characterized by
progressive neurodegeneration and arises from mu-
tations in the NPC1 gene on chromosome 18 [7,8]
and is fatal autosomal recessive neurovascular disor-
der [4] characterized by the progressive neurodegenra-
tion of central nerve system, which leads to premature
death [3]. Cells lacking functional NPC1 accumulate
cholesterol in the lysosomal and late endosomal com-
partment [41]. At the cellular level, the most prominent
feature of the NP-C lesion is lysosomal sequestration
of low density lipoprotein (LDL) derived cholesterol,
resulting in downstream effects on cholesterol home-
ostasis [48]. These lipid disturbances are essentially
localized to gray matter. Like other lysosomal stor-
age disorder disease, NPC disease shows axonal ab-
normalities (spheroids, meganeurites, and axonal dys-
trophy) and demyelination of the corpus callosum [32,
∗Corresponding author: Kyung-Sun Kang, D.V.M., PhD, Tel.:
+82 2 880 1246; Fax: +82 2 876 7610; E-mail: kangpub@snu.ac.kr.
44]. NPC 1 gene was identified in 1997 and NPC1 is
an integral membrane protein consisting of 1278 amino
acids, and NPC 1 residues and cycles mainly late en-
dosome/lysosome and gogli apparatus [7].
The frequency of the Niemann pick diseases type C is
estimated at about 1 in 105 live births. The disease oc-
curs more frequently in people of French-Acadian de-
scent in Nova Scotia [47]. Symptoms usually may ap-
pear as early as a few months old or as late as adulthood.
In childhood on set form, delayed motor development
and hypotonia begin between 1 and 2 years of age and
most of them die before the age of 5 years [39]. NPC
young patients showed enlarged liver and spleen. En-
largement of the spleen and/or liver is associated with
an abnormal accumulation of fatty material including
cholesterol within the cell. In addition, Niemann Pick
type C disease gradually develop neurological prob-
lems include dystonia, dysarthria, learning difficulties,
and vertical supranuclear gaze palsy. It is known that
the carrier frequency of NPC is about 25%. When both
parents are carriers of NPC, the probability of having
an affected child increases with each pregnancy.
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Fig. 1. Neural stem cells (NSC) require NPC to self-renew normally. Images show typical neurospheres that formed after 7d from E16 fetal mice
brain. (a) Genotyping analysis with tail-DNA by RT-PCR. (b) Generation of NPC−/− E16 cerebral cells, the cells that formed multipotent
neurospheres was significantly reduced relative to wild-type cells. (c-d) Self-renewal capacity is expressed as the number and diameter of
secondary and tertiary neurospheres generated per primary neurospheres on subcloning. (e) Generated neurospheres were differentiated by 1%
fetal bovine serum, after 7d, the spheres were differentiated into astrocytes (GFAP) between wild-type+/+ and knock-out−/−. (f) Expression
of GFAP, pMKK3/6, MKK3, pp38, p38, pERK1/2, and ERK1/2 in wild-type, NPC+/−, and NPC−/− mice. Values are the mean± s.d. for
3–5 independent experiments. Scale bars, 100µ. (Reprinted, from Yang et al., 2006).
1.1. Stem cells in NPC disease
Neural stem cells (NSCs) are multipotential progen-
itor cells that are undifferentiated and capable of pro-
liferation, self-renewal, and the production of many
differentiated functional progenies [17]. Moreover,
engraftment of these cells leads to recovery in neu-
ropathological conditions [9,43]. NSCs possessing the
propensity for self-renewalin vitro grow in clonal ag-
gregates called “neurospheres” and may provide an un-
limited source of cells for grafting into patients with
Parkinson’s disease [42], Hungtington’s disease [28],
and multiple sclerosis [24]. For these reasons, ba-
sic studies aiming to well characterize the biology of
NSCs are of great interest. These cells are exposed
to a high concentration of mitogens such as epidermal
growth factor (EGF) or basic fibroblast growth factor
(bFGF) and can be induced to differentiate by with-
drawing the mitogens or by adding differentiating sub-
stances [49]. Behavior of NSCs in culture is affected by
multiple variables including: species, growth medium,
passage method (dissociated spheres, chopped spheres,
and bioreactor) [2,16]. Moreover, the ability of imma-
ture progenitors and stem cells contained in thein vitro
expanded spheres to differentiatein vivo into mature
neurons and glia is still unclear. Recently, Milosevic
et al. reported spontaneous apoptosis in murine free-
floating neurosphere by activation of caspase-3 and
Bcl-2 family [30].
Neural stem cells (NSCs) are capable of giving rise
to neurons, glia- and astrocytes. Although self renewal
and differentiation in neural stem cells are regulated by
many genes such as Notch, Numb etc., little is known of
the role of defective genes on the self renewal and dif-
ferentiation of neural stem cells in the developingbrain.
The Niemann-Pick type C1 (NPC1) disease is one of
the neurodegenerative diseases, caused by a mutation
of NPC1 gene, which affects the function of NPC1 pro-
tein. The ability of NSCs self renewal and differenti-
ation was investigated using a model of Niemann-Pick
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Fig. 2. NPC deficiency increases expression of astrocyte and induces morphological differentiation in astrocyte. (a) Cerebral cells from E16
NPC−/− mice were dissociated and cultured to generate neurospheres in the presence of MEK inhibitor 2µM PD98059 and p38 MAP kinase
inhibitor 2µM SB202190. (b-c) Self-renewal capacity is expressed as the number and diameter of secondary and tertiary neurospheres generated
per primary neurospheres on subcloning. (d) Expression of GFAP, pMKK3/6, pp38 and pERK1/2 were reduced in the neurosphere-derived cells
treated with PD98059 and SB202190. Western blotting was done on neurosphere-derived cells (25µg of protein) from each mouse. Scale bars,
100µ. (Reprinted, from Yang et al., 2006).
type C1 (NPC1) disease. The NPC1 disorder signif-
icantly affected the self renewal ability and differen-
tiation of neural stem cells. Neural stem cells from
NPC1−/− mice showed impaired self renewal ability
when compared to theNPC1+/+ mice [50]. These al-
terations were accompanied by the enhanced activity
of p38 MAP kinases. Further, the specific p38 MAP
kinase inhibitor, SB202190 improved the self renewal
ability of NSCs fromNPC1−/− mice (Fig. 2). This
indicates that the NPC1 deficiency can lead to lack of
self renewal and altered differentiation of neural stem
cells mediated by the activation of p38 MAP kinase im-
pairing the generation of neurospheres fromNPC1−/−
(Fig. 3). Thus the NPC1 gene may play a crucial role
in NSC self-renewal associated with p38 MAP kinase.
1.2. Biomarkers in NPC
A biomarker is generally indicator of presence or
extent of a biological state that is itself directly linked
to the clinical symptoms and indicates particular dis-
eases [22]. Niemann pick type C showed the het-
erogeneity due to the onset time or individual differ-
ences [34,47]. Many studies have identified biomark-
ers for Niemann pick disease [11,14,47]. In particu-
lar, NPC is difficult to diagnose when patients showed
typical psychiatric disorder, frontal dementia, atax-
ia or dystonia and various neurological signs seen in
NPC which are similar to other neurological diseases
such as Alzheimer’s disease, Parkinson’s disease and
schizophrenia and so on [39]. Therefore, more bio-
logical markers are needed to confirm and treat NPC
diseases. Previously, we found out NPC1 gene leads
to the lack of the self renewal ability of stem cells as-
sociated with p38 MAPK kinase. It could be consid-
ered as a new biomarker for NPC. Recently, stem cell-
related genes have been proven to be good biomark-
ers in several diseases such as cancer and cardiovas-
cular diseases. To investigate whether the differences
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Fig. 3. Schematic diagram for expression and function of NPC1 gene is mediated by MAP kinase in regulation of neuronal stem cell self renewal
and differentiation. Neuronal stem cells were isolated from brain of wild type and NPC−/− mice; it was affected to self renewal ability and
differentiation of neuronal stem cell not through the MAP kinase (pERK, pp38) depending on NPC1 gene presence. MAP kinase inhibitors, PD
98059(MEK inhibitor), SB202190 (p38 inhibitor) could induce improvement of self renewal ability in neuronal stem cell from NPC1−/−.
of gene expression profiles of brain (8 weeks, hip-
pocampus) derived form NPC1−/− and+/+ mice,
we utilized a whole genome bead-based technology
(Expression BeadChip for the analysis of> 46,000
mouse targets based on the Ref Seq, RIKEN FANTOM
2 database, and other data sources) developed by Illu-
mina Inc. that combines the sensitivity and low cost
of a focused array with the coverage of a large-scale
array [20]. Many more genes (approximately 90%)
were found to be significantly up-regulated than down-
regulated in NPC1−/− mice compared with NPC1
+/+ mice. The major GO (Gene Ontology) Biolog-
ical Process terms’ relative abundance are illustrated
in Fig. 4. NPC1 gene deficiency regulates the expres-
sion of genes related to a variety of biological pro-
cesses. GO biological processes enriched in differen-
tially expressed genes were identified using binomi-
nal test [12] as implemented in the Panther Classifica-
tion System (http://www.pantherdb.org) [46]. The test
showed that the genes involved in biological process-
es such as immunity and defense, developmental pro-
cesses, cell proliferation and differentiation, T-cell me-
diated immunity, complement-mediated immunity and
MHCI-mediated immunity were significantly enriched
(P < 0.05) in genes up-regulated in NPC1−/− mice.
NPC1 gene deficiency also altered the expression of
genes related to a broad range of pathways, with an-
giogenesis, inflammation mediated by chemokine and
cytokine signaling pathway, blood coagulation and wnt
signaling pathway (Fig. 5). The inset pie chart illus-
trates the subdivision of the each pathway category.
The most genes were associated with immunity and
defense. NPC1−/− mice derived brain showed high-
er gene expression values for lectin, galactose binding,
soluble 3 (Lgals3, Gal3, GBP, L-34 and Mac-2) and
lectin, galactoside-binding, soluble, 3 binding protein
(Lgals3bp, 90 K, CyCAP, MAC-2BP, Ppicap) com-
pared to NPC1+/+ mice. Galectin-3, microglia dif-
ferentiation and differentiation marker, is involved in a
variety of biological functions, including cell prolifer-
ation and differentiation, inflammation, tumor cell ad-
hesion, angiogenesis, tumor progression and metasta-
sis [6].
Inflammation is mediated by both molecular com-
ponents, including cytokines, and cellular components,
mainly microglia, many of which have pro- and/or anti-
inflammatory properties [40]. Increased levels of two
glial proteins related to the inflammatory response have
been observed in Alzheimer’s transgenic mice: glial
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Fig. 4. Major Gene Ontology Biological Process associated with NPC1 gene deficiency. Pie chart indicating GO Biological Process annotations
related to NPC1 gene deficiency. Sizes of slices are indicative of probe sets with annotations.
fibrillary acidic protein (GFAP), which overexpression
was confirmed by western blotting, and the comple-
ment protein C1q. Chronic inflammation has been
consistently observed in the brains of AD patients or
transgenic (Tg) mice developing amyloid plaques [10].
Characteristic inflammatory features are the presence
of activated microglial cells and reactive astrocytes
surrounding plaques, as well as the expression of in-
flammatory mediators such as cytokines or comple-
ment factors [10]. GFAP, an intermediate filament pro-
tein specifically expressed in astrocytes, is dramatical-
ly up-regulated during reactive astrogliosis [29]. This
suggest that astrocyte modifications are more likely
to be a consequence of neuronal damage. Our study
showed abnormal differentiation of astrocyte pheno-
type in NPC1−/− and slightly increased GFAP pro-
tein levels but no significant difference between wild
type and NPC1 deficient mice [50]. C1q is the ini-
tial component of the classical complement pathway,
and it can be secreted by both microglia and astro-
cytes. The absence of C1q in Tg mice decreases the
level of activated glia without changing the number of
amyloid plaques compared to regular Tg animals [15].
The level of both GFAP and C1q was reported to be
increased in AD patient brain samples [35,51]. The
glycosylation of GFAP was also shown to be increased
in AD brains [25]. Moreover, immunochemistry stud-
ies showed that GFAP and C1q are concentrated in
the surrounding of plaques: GFAP was found in re-
active astrocytes, and C1q was observed in microglia
and amyloid plaques, both in AD patients brain sam-
ples and transgenic mouse brains [1,26]. Genes in-
volved in GFAP and several complement components
were also up-regulated, suggestion of an alteration in
the immunity or/and inflammatory response. Choles-
terol accumulation has been a hallmark of the NPC1
disease but the relationship between this accumulation
and neurodegeneration remains a mystery. Cholesterol
accumulation showed a marked increase in 8 weeks in
NPC1−/− mice, correlating strongly with the devel-
opment of symptoms [5]. Genes encoding cholesterol-
related proteins (Anxa2, Anxa3 and Cav1) and protein
kinase C were up and down-regulated, respectively, in
NPC1−/− mice. These findings of mRNA level were
in agreement with the result of others. Heterozygous
and homozygous mice with NPC have an increased
expression of caveolin-1 in liver homogenates [18].
Caveolin-1 is responsible for maintaining cholesterol
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levels by promoting the efflux of excess intracellular
unesterified cholesterol. Since the transport of LDL-
derived cholesterol is impaired in NPC and cells accu-
mulate LDL-derived cholesterol, this excess intracellu-
lar cholesterol may result in an increase in caveolin-1
expression. Like caveolin-1, annexin 2 has been found
to be associated with caveolae and intracellular vesi-
cles [33,37,38]. Annexin 2 is a lipid-binding protein
that is widely involved in facilitating intracellular trans-
port, including endocytic trafficking, and is reported to
associate with membrane microdomains and normally
localizes to early endosomes but has been shown to be
mislocalized because of lipid accumulation in late en-
dosomes in NPC disease [13,21,27,31]. Both caveolin-
1 and annexin 2 contained PKC phosphorylation con-
sensus sequences, although only annexin 2 serves as
a direct substrate for PKC [19,45]. Caveolin-1 is, in-
stead, serine phosphorylated by casein kinase IIα (CK
IIα), which is, in turn, activated by PKC [36]. NPC1
deficiency led to lack of self-renewal ability and altered
morphology of astrocytes in fetal cerebral cells at day
E16 through the activation of p38 MAPK [50]. Even
if gene expression in hippocampus was investigated
in 8-week-old NPC mice, genes encoding p38γ and
MEKK1, one of 38γ upstream, were also slightly up-
regulated in NPC1−/− mice. Gene expression anal-
ysis of NPC mice has revealed many intriguing sim-
ilarities with classic neurodegenerative disease. Fur-
ther study of newly identified candidate genes provide
insight into the understanding of the basic mechanism
through perturbation of gene networks in a single gene
knockout model of NPC disease.
1.3. Targeted therapeutics and new research in NPC
Currently, there is no effective treatment for NPC
disease patients. Several pharmacological treatments
have been used for it to reduce cholesterol accumula-
tion or neurological symptoms or low cholesterol di-
et is recommended. However, low cholesterol diet or
cholesterol lowering drugs didn’t change the choles-
terol metabolism level or progression of diseases. Gene
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therapy is considered a good treatment for NPC dis-
ease but there are many difficulties such as gene de-
livery technique. In fact, there are no efficient sys-
tems to deliver genes to the brain [22]. Recently, one
of the promising treatments is stem cell-based therapy.
Stem cells have been transplanted into Parkinson dis-
ease patients and laboratory models with variable out-
comes [23]. Therefore, we can use stem cell therapeu-
tics for NPC disease in the future, possibly using adult
stem cells including Umbilical cord blood-derivedstem
cells and so on. Another therapeutic approach is that
there is a link between the lack of self renewal of neu-
ral stem cell and some of the neuropathological symp-
toms seen in NPC1 patients. Thus anti-MAP kinase
agents could be of therapeutic importance in patients
with the NPC 1 disorder. In our previous work, NPC1
deficiency led to lack of self renewal ability and al-
tered morphology of astrocytes through the activation
of p38 MAP kinase, suggesting that p38 MAP kinase
inhibitors may be effective method for increasing self-
renewal of neural stem cells for clinical application in
NPC1 disease (Fig. 3). It is clear that a greater under-
standing of the exact mechanism of self-renewal and
the function of the NPC1 protein should provide bet-
ter insights into the application of stem cell therapy in
neurodegenerative diseases.
2. Conclusions
It is clear that a greater understanding of the ex-
act mechanism of self-renewal and the function of the
NPC1 protein should provide better insights into the
application of stem cell therapy in neurodegenerative
diseases. We conclude that NPC1 gene may be a can-
didate gene for controlling self-renewal of neural stem
cells throughout life – in addition to a pharmacological
reagent.
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